HAENYSESurgical & Medical Instruments & ApparatusFiscal year ends April 3
HAEMONETICS CORP
Financials through Q1 FY2027, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 6, 2026
$118.73+0.45 (+0.38%)
Close on Oct 19, 2026
- Market cap
- $5.43B
- P/E (TTM)
- 57.9
- Dividend yield
- –
HAEMONETICS CORP revenue by segment
By business segment
| Revenue | Q1 27 | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apheresis | $191.32M | – | – | – | $181.74M | – | – | – | – | – | – | – | 56.4% | +5.3% |
| Med Surg | $148.06M | – | – | – | $139.66M | – | – | – | – | – | – | – | 43.6% | +6.0% |
| Hospital | – | $159.65M | $143.50M | $145.50M | $139.66M | $147.86M | $143.97M | $138.42M | $134.02M | – | – | – | – | – |
| Blood Center | – | $56.41M | $56.56M | $56.45M | $51.84M | $56.01M | $70.35M | $68.53M | $66.25M | – | – | – | – | – |
| Plasma | – | $130.29M | $138.91M | $125.36M | $129.90M | $126.74M | $134.22M | $138.56M | $135.91M | – | – | – | – | – |
| Business Unit | – | – | – | – | – | – | – | – | – | $338.05M | $330.70M | $313.14M | – | – |
| Operating income | Q1 27 | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apheresis | $56.55M | – | – | – | $59.18M | – | – | – | – | – | – | – | -4.4% |
| Med Surg | $22.71M | – | – | – | $18.38M | – | – | – | – | – | – | – | +23.6% |
| Hospital | – | $29.57M | $25.92M | $29.86M | $18.38M | $21.79M | $27.39M | $23.28M | $16.52M | -$79.93M | $49.36M | $41.83M | – |
| Blood Center | – | $11.24M | $13.03M | $14.83M | $10.89M | $9.92M | $14.32M | $15.80M | $12.78M | -$38.87M | $27.65M | $27.31M | – |
| Plasma | – | $43.69M | $50.23M | $42.59M | $48.29M | $50.63M | $47.73M | $44.43M | $41.72M | -$52.22M | $80.45M | $78.04M | – |
By product or service
By region
| Revenue | Q1 27 | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $257.84M | $251.97M | $247.71M | $240.09M | $242.40M | $248.29M | $257.67M | $256.06M | $248.90M | $245.79M | $250.80M | $236.35M | 76.0% | +6.4% |
| Europe | $45.53M | $52.90M | $48.28M | $42.97M | $40.88M | $42.28M | $44.16M | $41.99M | $47.23M | $45.05M | $37.04M | $38.67M | 13.4% | +11.4% |
| Rest of Asia | $20.16M | $19.97M | $23.03M | $22.57M | $21.65M | $21.16M | $25.60M | $25.77M | $19.78M | $26.83M | $30.94M | $27.74M | 5.9% | -6.9% |
| Japan | $12.86M | $18.40M | $18.14M | $18.01M | $13.65M | $16.11M | $16.17M | $16.42M | $13.71M | $16.48M | $14.83M | $15.01M | 3.8% | -5.8% |
| Other | $2.99M | $3.11M | $1.81M | $3.68M | $2.81M | $2.77M | $4.94M | $5.27M | $6.56M | $9.15M | $2.65M | $426.00K | 0.9% | +6.2% |
From the segment and revenue-disaggregation notes of Haemonetics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.